Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) drugs are no longer in short supply, U.S. regulators said Feb. 21, 2025, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
Steve Christo/Corbis/Getty Images
https://fortune.com/img-assets/wp-content/uploads/2025/02/GettyImages-2193602916-e1740168016500.jpg?resize=1200,600
2025-02-21 20:03:47
